Skip to content
Search

Latest Stories

Trifluoperazine supplies to resume in mid-September

The Trifluoperazine 1mg/5ml syrup will remain out of stock, according to an update from the Pharmaceutical Services Negotiating Committee (PSNC) the supplies are expected to resume mid-September 2021.

Earlier, the Department of Health and Social Care (DHSC) had issued a medicine supply notification for Trifluoperazine 1mg/5ml syrup, stating it would remain out of stock until April 2021 which has been further extended till mid of September.


However, Trifluoperazine 1mg and 5mg tablets were available to support an increase in demand.

Further to support any increase in demand, specials manufacturers had confirmed to manufacture the medicine in 1mg/5ml oral suspension.

Anyone prescribing a product that is not licensed in the UK must indicate on the FP10 prescription that an unlicensed product is required. This can be done by annotating the prescription with the wording “Special Order”, as per the DHSC notification.

Currently, the medicine is not listed on the NHS Dictionary of Medicines and Devices (dm+d) for prescribers.

However, if a prescriber wishes to prescribe an unlicensed import, a paper prescription should be issued as ‘Trifluoperazine 1mg/5ml oral suspension (Special Order)‘and endorsed by the pharmacy as a non-Part VIIIB special.

The paper should also have a mention of amount dispensed over pack size used, invoice price per pack size, manufacturers’/importers’ Medicines and Healthcare Products Regulatory Agency (MHRA) licence number, batch number of the product supplied.

More For You

Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less